<DOC>
	<DOCNO>NCT00106535</DOCNO>
	<brief_summary>This 3 arm study compare safety efficacy , respect reduction sign symptom prevention joint damage , tocilizumab versus placebo , combination methotrexate ( MTX ) patient moderate severe active rheumatoid arthritis . Patients randomize receive tocilizumab 4 mg/kg IV , tocilizumab 8 mg/kg IV placebo IV , every 4 week . All patient also receive methotrexate , 10-25 mg/week . The anticipated time study treatment 1-2 year target sample size 500+ individual . After completion 2 year study participant could participate optional 3 year open label extension phase ( year 3 5 ) .</brief_summary>
	<brief_title>A Study Assess Effect Tocilizumab + Methotrexate Prevention Structural Joint Damage Patients With Moderate Severe Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient least 18 year age moderate severe active RA least 6 month ; inadequate response stable dose MTX ; patient reproductive potential must use reliable method contraception . major surgery ( include joint surgery ) within 8 week enter study , plan surgery within 6 month enter study ; prior treatment failure antitumor necrosis factor agent ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>